A previous clinical trial targeting R/R NHL with CD19/CD20 bispecific CAR-T cells reported an overall response rate (ORR) of 90% and a complete response (CR) rate of 70% [47]; of note, one patient experienced relapse at 18 months but achieved CR after receiving the second dose of CAR-T cells. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.